Neumann, Johannes Tobias http://orcid.org/0000-0002-9478-2757
Twerenbold, Raphael http://orcid.org/0000-0003-3814-6542
Ojeda, Francisco
Aldous, Sally J.
Allen, Brandon R.
Apple, Fred S.
Babel, Hugo
Christenson, Robert H.
Cullen, Louise
Di Carluccio, Eleonora
Doudesis, Dimitrios
Ekelund, Ulf
Giannitsis, Evangelos
Greenslade, Jaimi
Inoue, Kenji
Jernberg, Tomas
Kavsak, Peter
Keller, Till
Lee, Kuan Ken
Lindahl, Bertil
Lorenz, Thiess
Mahler, Simon A.
Mills, Nicholas L.
Mokhtari, Arash
Parsonage, William
Pickering, John W.
Pemberton, Christopher J.
Reich, Christoph
Richards, A. Mark
Sandoval, Yader
Than, Martin P.
Toprak, Betül
Troughton, Richard W.
Worster, Andrew
Zeller, Tanja
Ziegler, Andreas
Blankenberg, Stefan
,
Brownlee, Emily
Eggers, Kai M.
Fincher, Gavin
Frey, Norbert
Gaikwad, Niranjan
Gangathimmaiah, Vinay
Hall, Emma
Haller, Paul M.
Hamilton-Craig, Christian
Hancock, Rebecca
Hobbins-King, Andrew
Keijzers, Gerben
Bayat, Maryam Khorramshahi
Koliopanos, Georgios
Lehmacher, Jonas
Ljung, Lina
Madsen, Troy
Mahmoodi, Ehsan
McCormick, Ellyse
Mumma, Bryn
Nowak, Richard
Blazquez, Vanessa
Perez, Siegfried
Qaderi, Vazhma
Ranasinghe, Isuru
Schock, Alina
Sörensen, Nils A.
Staib, Andrew
Stephensen, Laura
Weaver, Michael
Wilkerson, R. Gentry
Zournazi, Anna
Clinical trials referenced in this document:
Documents that mention this clinical trial
Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes (Results)
https://doi.org/10.2337/dc19-1327
Long-term outcome of patients presenting with myocardial injury or myocardial infarction
https://doi.org/10.1007/s00392-023-02334-w
Diagnostic performance of a device for acoustic heart sound analysis in patients with suspected myocardial infarction
https://doi.org/10.1136/openhrt-2022-002090
Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction
https://doi.org/10.1007/s00392-019-01475-1
Personalized diagnosis in suspected myocardial infarction
https://doi.org/10.1007/s00392-023-02206-3
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 15 March 2023
Accepted: 11 April 2023
First Online: 2 May 2023
Declarations
:
: SB receives fundings from Abbott Diagnostics, Bayer, SIEMENS, Amgen and NOVARTIS as well as honoraria for lectures and/or chairs from Abbott, Abbott Diagnostics,, AMGEN, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS (Bristol Meyer Squib), Daiichi Sankyo, LumiraDx, NOVARTIS and Thermo Fisher. SB is a member of advisory boards and consultant of Thermo Fisher. JTN, RT, FO, TZ, AZ and SB are co-founders and shareholders of the ART-EMIS Hamburg GmbH, which holds an international patent application on the use of a computing device to estimate the probability of myocardial infarction (Publication Numbers WO2022043229A1, TW202219980A). JTN reports speaker honoraria/consulting honoraria from PHC, Roche and Siemens. RT reports research support from the Kühne Foundation, the Swiss National Science Foundation (Grant No P300PB_167803), the Swiss Heart Foundation, the Swiss Society of Cardiology and speaker honoraria/consulting honoraria from Abbott, Amgen, Astra Zeneca, Roche, Siemens, and Singulex. BRA receives research funding/support from Roche Diagnostics, Siemens, and Beckman Coulter. BRA is a consultant for Roche Diagnostics. FSA is a consultant for HyTest Ltd and an associate Editor for Clinical Chemistry. FSA is part of the advisory boards of Werfen, Siemens Healthineers, Qorvo and AWE Medical Group. FSA receives honorarium for speaking at industry conferences of Siemens Healthineers and Beckman Coulter. FSA is PI on Industry Funded Grants (non-salaried) on cardiac biomarkers through Hennepin Healthcare Research Institute for Abbott Diagnostics, Abbott POC, BD, Beckman Coulter, Ortho-Clinical Diagnostics, Roche Diagnostics, Siemens Healthcare, ET Healthcare and Qorvo. RHC is a consultant for and receives funding/support from Roche Diagnostics, Siemens Healthineers, Beckman Coulter Diagnostics, Becton Dickinson and Co, Quidel Corp, and Sphingotec GMBH. LC reports research funding from Siemens, Abbott, and Beckman. EG reports personal fees from Bayer Vital, personal fees from Astra Zeneca, personal fees from Roche Diagnostics, personal fees from Brahms Germany, personal fees from Daiichi Sankyo, personal fees from Lilly Deutschland, outside the submitted work. EG reports participation on a Data Safety. Monitoring Board or Advisory Board at Boehringer Ingelheim and Roche Diagnostics. JG receives grants from Siemen´s Point of Care and Beckman Coulter. KI receives grants from Japanese KAKENHI (grant number JP18K09554). KI reported payment for honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche Diagnostics to Fujirebio Inc. PK reports support for this manuscript to his institution from Canadian Institutes of Health Research, Abbott Diagnostics and Roche Diagnostics. PK reports grants for his institution from Abbott Diagnostics, Roche Diagnostics, Randox laboratories, Beckman Coulter, Ortho Clinical Diagnostics and Siemens Healthcare Diagnostics. PK receives consulting fees from Abbott, Beckman Coulter, Roche Diagnostics, Quidel and Siemens Healthcare. PK receives reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Beckman Coulter, Roche Diagnostics, Siemens Healthcare and Thermo Fisher Scientific. PK receives support for attending meetings and/or travel from Randox Laboratories ans Roche Diagnostics. McMaster University has filed a patent with PK listed as an inventor in the acute cardiovascular biomarker field, in particular, a patent has been awarded in Europe (EP 3 341 723 B1) on a Method of determining risk of an adverse cardiac event. McMaster University has also filed patents with PK listed as an inventor on Quality Control Materials for Cardiac Troponin Testing and Identifying pregnant women at increased risk for hypertension and future cardiovascular disease. PK reports participation on a Data Safety Monitoring Board or Advisory Board for Roche Diagnostics, Siemens Healthcare Diagnostics, Beckman Coulter and Quidel. BL is a member (unpaid) of Study Group on Biomarkers of the ESC Association for Acute CardioVascular Care. SAM receives research funding/support from Roche Diagnostics, Abbott Laboratories, Ortho Clinical Diagnostics, Creavo Medical Technologies, Siemens, Pathfast, Grifols, Rigel Pharmaceuticals, the Agency for Healthcare Research and Quality, the Patient-Centered Outcomes Research Institute, the National Heart, Lung, and Blood Institute (1 R01 HL118263-01), and the Health Resources and Services Administration (1 H2ARH399760100). Dr Mahler is a consultant for Roche Diagnostics and Amgen and is the chief medical officer for Impathiq Inc. NLM reported grants from British Heart Foundation to his institution (CH/F/21/90010, RG/20/10/34966, RE/18/5/34216). NLM has received honoraria or consultancy from Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, and LumiraDx. NLM reports participation on an Advisory Board of LumiraDx, Roche Diagnostics and Siemens Healthineers. NLM is supported by a Chair Award, Programme Grant, Research Excellence Award (CH/F/21/90010, RG/20/10/34966, RE/18/5/34216) from the British Heart Foundation. JWP has received non-directed funds from Abbott Diagnostics, Roche, Siemens within the last 5 years and consulted for Abbott. CJP receives Project grants from the Health Research Council of New Zealand and from the Heart Foundation of New Zealand. He is PI on grants hosted by University of Otago. CJP received project grant from the Ministry of Business, Innovation and Employment, New Zealand. CJP is inventor on patents (granted and filed) for the diagnosis of acute coronary syndromes. CJP is CSO at Upstream Medical Technologies. CJP reported research support from Upstream Medical Technologies and from Biovendor R&D. AMR reports speaker honoraria/advisory board fees and research grants in kind and/or cash funding from Roche Diagnostics, Astra Zeneca, Abbott Laboratories, Novartis, NovoNordisk, Thermo Fisher, Critical Diagnostics, Sphingotec, Medtronic and Boston Scientific. AMR reports grants from National Medical Council of Singapore and NovoNordisk research grants. He has received publicly contestable funding from the New Zealand Health Research Council, NZ Heart Foundation and the National Medical research Council of Singapore. AMR reports personal fees from Roche Diagnostics, Novartis and Roche Diagnostics. AMR reports participation on a Data Safety Monitoring Board or Advisory Board in the Pontiac 2 trial and STAREE Trial. YS has previously served on Advisory Boards for Roche Diagnostics and Abbott Diagnostics. YS has also been a speaker for Abbott Diagnostics. WP reported research grants and consulting fees to his institution from Siemens Healthineers. MPT received Funding for clinical research from Abbott, Alere, Beckman, Radiometer and Roche (to his institution). MPT received payment for speaking from Abbott, Alere, and Roche as well as Consulting fees from Abbott, Roche and Siemens. MPT received payment for participation in advisory boards from Abbott, Radiometer, Roche and Siemens as well as funding for education from Abbott, Alere and Beckman (to his institution). BT receives a project-related grant from German Heart foundation and from the Ernst und Berta Grimmke-Stiftung. RWT received payments to his institution from Health Research Council of NZ, Heart Foundation of NZ, American Regent, Merck and Bayer. RWT receives consulting fees from American Regent, Merck, Bayer and Roche Diagnostics.AW is having a patent on the Clinical Chemistry Score. TZ is supported by the German Centre for Cardiovascular Research (DZHK e.V.) grant numbers 81Z1710101 and 81Z0710102.TZ is supported by EU Horizon 2020 programme and EU ERANet and ERAPreMed Programmes.